Form 4: Dianthus Therapeutics, Inc. /DE/ Director Sells Shares
Insider Transaction (Form 4)
Simon Read, a Director of Dianthus Therapeutics, Inc. /DE/, sold 2,777 shares of common stock on August 10, 2026.
Summary
- Option exercise/conversion: acquired 2,777 Common Stock at $18.36 ($50,986) on August 10, 2026; holds 2,777 after (Direct).
- Open-market sale: disposed of 70 Common Stock at $107.11 ($7,498) on August 10, 2026; holds 2,707 after (Direct).
- Open-market sale: disposed of 737 Common Stock at $108.17 ($79,721) on August 10, 2026; holds 1,970 after (Direct).
- Open-market sale: disposed of 831 Common Stock at $108.95 ($90,537) on August 10, 2026; holds 1,139 after (Direct).
- Open-market sale: disposed of 272 Common Stock at $109.96 ($29,909) on August 10, 2026; holds 867 after (Direct).
- Open-market sale: disposed of 470 Common Stock at $111.05 ($52,194) on August 10, 2026; holds 397 after (Direct).
- Open-market sale: disposed of 397 Common Stock at $111.77 ($44,373) on August 10, 2026 (Direct).
- Option exercise/conversion: disposed of 2,777 Stock Option (Right to Buy) on August 10, 2026; holds 22,223 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $304,232 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Simon Read — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-10 | Option exercise/conversion | Common Stock | 2,777 | $18 | $51.0K | 2,777 |
| 2026-08-10 | Open-market sale | Common Stock | 70 | $107 | $7.5K | 2,707 |
| 2026-08-10 | Open-market sale | Common Stock | 737 | $108 | $79.7K | 1,970 |
| 2026-08-10 | Open-market sale | Common Stock | 831 | $109 | $90.5K | 1,139 |
| 2026-08-10 | Open-market sale | Common Stock | 272 | $110 | $29.9K | 867 |
| 2026-08-10 | Open-market sale | Common Stock | 470 | $111 | $52.2K | 397 |
| 2026-08-10 | Open-market sale | Common Stock | 397 | $112 | $44.4K | 0 |
| 2026-08-10 | Option exercise/conversion | Stock Option (Right to Buy) | 2,777 | — | — | 22,223 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-10 | Option exercise/conversion (2,777 shares) |
| 2026-08-10 | Open-market sale (70 shares) |
| 2026-08-10 | Open-market sale (737 shares) |
| 2026-08-10 | Open-market sale (831 shares) |
| 2026-08-10 | Open-market sale (272 shares) |
| 2026-08-10 | Open-market sale (470 shares) |
| 2026-08-10 | Open-market sale (397 shares) |
| 2026-08-10 | Option exercise/conversion (2,777 shares) |
Keywords
insider transaction, Form 4, DNTH, Dianthus Therapeutics, Inc. /DE/, bearish, Simon Read
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.